Why is Astrazeneca Phar falling/rising?

As of 14-Jul, Astrazeneca Pharma India Ltd's stock price is currently at 9,171.40, reflecting a decrease of 65.2 points or 0.71%. Today's price summary indicates that the stock has underperformed its sector by 1.61%, with a notable decline in investor participation, as evidenced by a 19.68% drop in delivery volume compared to the 5-day average. Despite this, the stock has shown strong performance over the longer term, with a year-to-date return of 25.04% and a remarkable 36.77% increase over the past year. The company has demonstrated high management efficiency with a return on equity of 19.06% and has reported significant growth in net profit, which may support its valuation. However, the stock is considered expensive with a high price-to-book value ratio and has seen a decline in institutional investor participation, which could negatively impact its price movement.
In the broader market context, Astrazeneca's short-term performance contrasts with the benchmark Sensex, which has declined by 1.42% over the past week while Astrazeneca's stock has increased by 0.46%. This indicates that, despite the recent price drop, the stock has managed to perform relatively better than the overall market in the short term. However, the company's long-term growth prospects are questioned due to a slower growth rate in operating profit and a high PEG ratio, suggesting that while the stock has historically outperformed the market, current conditions may be leading to a reassessment of its valuation and future potential.